Project Grant R03CA292973
Award Date
7/17/24
Completion Date
7/16/26
Dollars Obligated
$145K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK 73104, USA
Similar Awards
This Project Grant award, totaling $103,948, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The funding supports research to investigate the role of the Ran guanine exchange factor, RCC1, in driving the progression of pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of pancreatic cancer. The research aims to use state-of-the-art transcriptomics and metabolomics approaches to elucidate how...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $616,495 to The University of Texas M.D. Anderson Cancer Center to investigate the role of sulfatide metabolism in pancreatic cancer precursor lesions. The key objectives are to: Define the biological functions of sulfatides in the development and progression of pancreatic cancer precursor lesions, such as intraductal papillary mucinous neoplasm (IPMN). This will involve using...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at identifying and disabling new pathways for macromolecular recycling in pancreatic cancer. The key objectives are to: 1) explore the role of the lysosomal hydrolase PLBD1 in supporting pancreatic cancer cell metabolism and growth, 2) dissect how the lysosomal hydrolase LGMN enables...
This $432,889 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to advance molecular imaging and metabolic therapies for reversing cachexia induced by pancreatic ductal adenocarcinoma (PDAC). The research team at The Johns Hopkins University will focus on disrupting glutamine metabolism in PDAC models, studying the effects on tumor and organ metabolism, as well as changes in the tumor and spleen immune...
This $1,130,538 federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to target the tumor-specific Tn antigen in pancreatic ductal adenocarcinoma (PDAC). The University of Louisville, as the prime awardee, will: Determine how the Tn antigen enhances PDAC tumor progression and identify Tn-expressing glycoproteins using mouse models and clinical specimens. Validate the role of natural killer cells in the...
This Project Grant award, titled "A NOVEL IMMUNOTHERAPY FOR PANCREATIC CANCER USING MICRO-RNA-29A," was provided by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) to the University of Miami in the amount of $107,948. The award will support research to determine the contribution of the TNFR2-miR-29a axis to CD8 T cell dysfunction in pancreatic ductal adenocarcinoma (PDAC), with the goal of generating durable T-cell mediated anti-tumor activity. The...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 in funding to Oncotab, Inc. to develop optimized targeted radiotherapy for pancreatic cancer. The key objectives are to conduct a structured design of experiments using an antibody targeting the tumor-associated MUC1 antigen, as well as a smaller tandem single-chain variable fragment (scFv) targeting agent. These will be labeled with alpha and beta particle-emitting...
This $370,575 project grant from the National Institutes of Health National Cancer Institute Cancer Biology Research program (CFDA 93.396) will fund research at the University of Cincinnati investigating the molecular mechanisms of growth in pancreatic cancer with GNAS mutations. The grant supports studies from August 1, 2022 to July 31, 2027 to further the understanding of the oncogenic functions of mutant GNAS and its downstream signaling pathways. Specifically, the research will illuminate...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $1,688,087 to the Sanford Burnham Prebys Medical Discovery Institute to conduct research on macropinocytosis inhibition as a strategy to sensitize pancreatic cancer to a glutamine mimetic drug. The key goals are to: (1) examine the role of macropinocytosis as a metabolic adaptation to the glutamine mimetic 6-diazo-5-oxo-L-norleucine (DON) in pancreatic ductal adenocarcinoma (PDAC)...
This $1,271,498 federal Project Grant award from the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396) supports research to develop a transgenic porcine model of pancreatic cancer for testing novel neoadjuvant therapies and endoscopic medical devices. The award recipient, the University of Nebraska Medical Center (UNMC), will leverage the size advantage of the porcine model to conduct studies that would not be feasible in mice. The overarching goal is to create a...